➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Johnson and Johnson
AstraZeneca
Merck
Baxter

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

Hoffmann-la Roche Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for HOFFMANN-LA ROCHE, and what generic alternatives to HOFFMANN-LA ROCHE drugs are available?

HOFFMANN-LA ROCHE has two approved drugs.

There are four US patents protecting HOFFMANN-LA ROCHE drugs.

There are ninety-four patent family members on HOFFMANN-LA ROCHE drugs in thirty-eight countries and nineteen supplementary protection certificates in fourteen countries.

Summary for Hoffmann-la Roche
International Patents:94
US Patents:4
Tradenames:2
Ingredients:2
NDAs:2
Patent Litigation for Hoffmann-la Roche: See patent lawsuits for Hoffmann-la Roche

Drugs and US Patents for Hoffmann-la Roche

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes 10,350,214   Start Trial Y   Start Trial
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes   Start Trial   Start Trial
Hoffmann-la Roche INVIRASE saquinavir mesylate TABLET;ORAL 021785-001 Dec 17, 2004 RX Yes Yes   Start Trial   Start Trial
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes   Start Trial   Start Trial
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes 9,440,922   Start Trial Y   Start Trial
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes 9,126,931   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Hoffmann-la Roche Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0432695 32/1996 Austria   Start Trial PRODUCT NAME: SAQUINAVIR UND SEINE SAEUREADDITIONSSALZE, INSBESONDERE SAQUINAVIRMESYLAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
2441753 2017/026 Ireland   Start Trial PRODUCT NAME: ALECTINIB OR SALT OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/16/1169/001 20170216
2441753 17C1019 France   Start Trial PRODUCT NAME: ALECTINIB OU SEL OU SOLVATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/16/1169 20170220
2441753 31/2017 Austria   Start Trial PRODUCT NAME: ALECTINIB ODER DESSEN SALZE ODER DESSEN SOLVATE; REGISTRATION NO/DATE: EU/1/16/1169 20170220
2441753 PA2017017,C2441753 Lithuania   Start Trial PRODUCT NAME: ALEKTINIBAS ARBA JO DRUSKA, ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/16/1169 20170216
2441753 PA2017017 Lithuania   Start Trial PRODUCT NAME: ALEKTINIBAS ARBA JO DRUSKA, ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/16/1169 20170216
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Medtronic
Baxter
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.